| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.93 | 1.94 | 3.78 | 2.85 | 7.69 | 2.89 | 6.78 | 1.65 | 2.97 | 6.00 | 0.41 | — |
| Quick Ratio | 1.93 | 1.94 | 3.78 | 2.85 | 7.69 | 2.89 | 6.78 | 1.65 | 2.97 | 6.00 | 0.41 | — |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -243.26% | -347.90% | -74.74% | -64.22% | -104.71% | -412.02% | -173.38% | -304.05% | -847.88% | -70.70% | 72.93% | — |
| ROA | -116.63% | -169.69% | -54.74% | -41.65% | -90.98% | -270.59% | -147.30% | -120.02% | -175.71% | -58.92% | -201.09% | — |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — | — |
| Book Value / Share | 3.02 | 1.02 | 3.29 | 8.45 | 0.63 | 0.44 | — | — | — | — | — | — |
MetaVia Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing multi-modal, disease-modifying therapies for serious metabolic and neurological conditions. The company concentrates on cardiometabolic diseases, including obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), as well as select central nervous system disorders. Its current pipeline includes DA-1726, being developed for obesity, and vanoglipel (DA-1241), a GPR119 agonist targeting MASH with potential relevance to Type 2 Diabetes Mellitus through modulation of gut hormones such as GLP-1, GIP, and peptide YY. MetaVia also develops ANA001, a proprietary oral niclosamide formulation, Gemcabene for acute indications including infectious and inflammatory settings, NB-01 for painful diabetic neuropathy, and NB-02 aimed at symptoms of cognitive impairment in neurodegenerative diseases. Operating within the biotechnology and health technology sectors, MetaVia plays a specialized role in addressing complex, high-burden diseases where there is significant medical need for new therapeutic options.